Lbp Am Sa Has $35.09 Million Stake in BioNTech SE Sponsored ADR $BNTX

Lbp Am Sa increased its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 368,584 shares of the company’s stock after acquiring an additional 15,255 shares during the quarter. Lbp Am Sa’s holdings in BioNTech were worth $35,089,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Financial Consulate Inc. bought a new position in shares of BioNTech during the 3rd quarter valued at about $36,000. Huntington National Bank boosted its holdings in shares of BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the period. Tower Research Capital LLC TRC increased its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of BioNTech by 40.8% during the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after acquiring an additional 227 shares during the period. Finally, Rakuten Securities Inc. raised its holdings in shares of BioNTech by 188.1% during the third quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock worth $103,000 after acquiring an additional 681 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of research analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research note on Wednesday, March 11th. TD Cowen dropped their price target on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. Raymond James Financial restated an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Morgan Stanley increased their price objective on BioNTech from $125.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Finally, Bank of America reissued a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $133.13.

BioNTech Stock Performance

BNTX opened at $99.47 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. The business has a fifty day simple moving average of $98.18 and a 200 day simple moving average of $101.03. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a market capitalization of $25.15 billion, a PE ratio of -18.98 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%.The business had revenue of $1.06 billion for the quarter. Research analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.